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ABSTRACT 
Objective 
 
To determine the link between the tumor necrosis factor induced protein 1(TNFAIP1) and 
TNF-a production in response to the P.gingivalis/LPS, and to investigate the mechanism 
that regulates the effect of the TNFAIP1 gene expression on TNF-a synthesis, using a new, 
simple, yet effective technique that allowed us to apply our methods on human 
macrophages.  
 
Materials and methods 
We performed several experiments including: A culture of mouse RAW cells and human 
THP-1 cells in RPMI media supplemented with 10% FBS at 37°C in 5% CO2, Polymerase 
Chain reaction (PCR) using specifically designed primers and DNA cloning of TNFAIP1, 
transfection of the cloned TNFAIP1 cDNA into macrophages, Western blot analysis, 
ELISA analysis after treatment in macrophages, and GFP imaging system.  
 
 
		 vi 
Results 
 
1. TNFAIP1 expression can reciprocally affect TNF-α production in macrophages. 
2. Blocking MAPK, PI3K and JAK downregulates the TNF-a production. 
3. The transfection of TNFAIP1 in THP-1 using a 1.5 ml Eppendorf tube generated a 
high transfection efficiency without the PMA treatment.  
4. TNFAIP1 induces Caspase 1 gene expression in macrophages. 
5. Caspase 1 induced by TNFAIP1 functions downregulation of TNF-a via p73.  
Conclusions 
 
1. MAP kinase, JAK, or PI3K, may be involved in TNF-α gene expression in LPS-
dependent pathway.  
2. TNFAIP1 expression can induce TNF-a production in mouse macrophages and 
vice versa. 
3. TNFAIP1 gene expression in response to LPS is independent of NFkB-
mediated signaling pathway.  
4. The animal model has been confirmed by using both mouse macrophage-like 
cells (RAW cells) and a human macrophage-like cells (THP-1 cells). 
5. The signaling pathway for the activation of TNF-a production in early stages 
is: LPS/ TNFAIP1/ PI3Kinase/AP-1/ TNF-a. 
6. TNFAIP1 acts as a suppressor in later stage to down-regulate TNF-α gene 
expression via the following signaling pathway: LPS/TNF-a/ TNFAIP1/ 
Caspase 1/ Apoptotic genes/ Degradation of TNF-α/ Cell apoptosis.  
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INTRODUCTION 
Porphyromonas Gingivalis and periodontitis: 
 Periodontal disease represents a group of inflammatory infections of the tooth 
supporting structures. They are complex, multifactorial conditions caused by an interaction 
between bacterial plaque and host defense mechanism. It ranges in severity from mild 
gingival inflammation (gingivitis), which is defined as an inflammation of the gingival soft 
tissue, to a chronic severe periodontitis, which refers to an irreversible inflammation of the 
periodontal ligaments and alveolar bone. The chronic state, in turn, may lead to migration 
of the epithelial attachment, destruction of the connective tissues surrounding the tooth and 
eventually tooth loss(1).  
Bacterial plaque has been implicated as the primary etiologic factor. Local and 
systemic factors may modify the microbial and host components. For example, local 
factors may affect the plaque accumulation and maturation, and systemic factors may 
modulate the host protective response(2). The initial physiologic response to the microbial 
challenge starts with acute inflammation as the immune system recruits adequate cells to 
the sites of infection through the production of cytokines and chemokines.(3)(4) If the 
infection fails to clear, a chronic lesion is initiated and the adaptive immune system is 
activated.(5) The	oral	cavity	harbors	over	6	billion	of	700	types	of	bacterial	species.	Studies	have	shown	that	a	very	small	proportion	of	bacteria	is	involved	in	the	initiation	and	progression	of	periodontal	disease.	Analysis	of	dental	plaque	samples	over	the	years	identified	specific	periodontal	pathogens,	mostly	gram-negative	anaerobic	bacteria,	
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that	colonize	subgingival	 tooth	sites.	Among	the	 findings,	 three	species	part	of	 the	“red	 complex”	 are	 frequently	 isolated	 together,	 and	 are	 strongly	 associated	 with	diseased	 sites	 in	 the	 mouth:	Porphyromonas	 gingivalis,	Treponema	
denticola	and	Tannerella	forsythia.	(6)(7)(8)	
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The complex multifactorial nature of periodontal disease is described in the figure 
below, it usually starts with an accumulation of bacterial plaque, which interacts with the 
host immune response resulting in a periodontal inflammation and tissue damage. 	
 
 
 
Figure 1. The pathogenesis of periodontal disease as described by Page and Kornman 
2000 (9) 
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The bacterial species exist in complexes in subgingival plaque, after analysis of 
13.261 plaque samples using whole genomic DNA probes and checkerboard DNA-DNA 
hybridization, 5 major bacterial complexes were identified. (A viscousus) were outliers 
with a little relation to the 5 major groups.	
 
 
 
 
 
 
 
Figure 2. Bacterial complexes as described by Socransky et al.1998(6) 
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Of this group, most evidence points to a pathogenic role 
for Porphyromonas gingivalis. The presence of this organism, either acting alone or as a 
mixed infection with other bacteria appears to be essential for disease activity. This species 
possesses a number of potential virulence factors, such as cysteine proteinases (gingipains), 
lipopolysaccharide (LPS), capsule and fimbriae. Porphyromonas gingivalis is a black-
pigmented, non-motile Gram-negative bacterium, requiring anaerobic conditions for 
growth, and the presence of heme or hemin and vitamin K in its nutrient environment. It 
gains its metabolic energy by fermenting amino acids, a significant property for its survival 
in deep periodontal pockets, where sugars are extremely limited. When considering its 
location in multispecies subgingival biofilm communities, P. gingivalis is a late colonizer, 
and hence is found in close proximity to and interacts with the juxtaposing gingival tissue 
(10)(11)(12)(13)(14). Lipopolysaccharide	 is	 a	 major	 component	 of	 the	 outer	 cell	membrane	of	gram	negative	bacteria,	including	Escherichia	coli,	Salmonella	enterica,	Neisseria	meningitidis,	Haemophilus	influenzae,	Bordetella	pertussis,	Pseudomonas	aeruginosa,	 Helicobacter	 pylori,	 Klebsiella	 pneumoniae,	 Legionella	 pneumophila,	Chlamydia	trachomatis	and	Porphyromonas	gingivalis.	LPS	 is	a	negatively	charged	heat	 stable	molecule,	 consisting	of	 a	 lipophilic	 lipid	portion	 linked	 to	a	 saccharide	group.(15)		
Gram negative bacterial cell walls serve as a physical barrier, as the LPS component 
of a cell wall is recognized by the immune system as a bacterial invasion, activating an 
immune defensive response against the pathogenic threat, which may cause serious 
inflammatory conditions leading to an endotoxic shock. The immune system then starts 
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fighting the bacterial invasion by recruiting a tremendous number of inflammatory cells, 
resulting in production of high concentrations of cytokines in blood, especially TNF-a.(16) 
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In Gram-negative bacteria, the cell wall is composed of a single layer of 
peptidoglycan surrounded by a membranous structure called the outer membrane. The 
outer membrane of Gram-negative bacteria invariably contains lipopolysaccharide (LPS) 
in addition to proteins and phospholipids. The LPS molecule is toxic and is classified as an 
endotoxin that elicits a strong immune response during bacterial infection.  
 
 
 
 
Figure 3. The structure of the Gram negative bacterial cell wall. 
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Epidemiological studies showed an evidence of association between periodontal 
infection and serious illnesses such as cardiovascular diseases, atherosclerosis (17), 
coronary heart disease and cerebrovascular and peripheral vascular diseases. People with 
periodontitis are at higher risk of developing atherosclerotic CVD (18), one of the top 
leading causes of death across the globe.  
Periodontitis produces a significant increase in the systemic inflammatory 
response, and inflammation is considered as an integrative risk factor for cardiovascular 
disease(19), with elevated levels of C reactive proteins as an indicator of future myocardial 
infarction(20). Patients with acute coronary syndromes have elevated levels of circulating 
cytokines such as IL-6, IL8, IL10 and TNF-a(20). Inflammation of periodontal tissues is 
related to biomarkers of endothelial dysfunction and dyslipidemia such as CRPs(21). 
Higher levels of CRPs were associated with periodontal infections with subgingival 
microorganisms including P.gingivalis(22). There is no direct causal relationship between 
periodontal disease and CVD. However, multiple studies have suggested two biologically 
plausible mechanisms as a link between Periodontal disease and CVD. First, direct 
translocation of bacterial pathogens from an ulceration in the inflamed periodontal pocket 
into the blood stream causes bacteremia. Ulcerated gingival epithelium in severe 
periodontitis locally produces proinflammatory cytokines, such as IL6- IL8- IL10 and 
TNF-a, which circulate and induce an acute-phase response in the liver, elevating levels 
of C reactive proteins(23). Indirectly, both periodontal inflammation and CVD share the 
same risk factors, including diabetes, smoking and obesity.(20) 
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Another mechanism to which periodontal inflammation contributes to 
atherogenesis and subsequently developing atherosclerosis and CVD, is described by 
H.Kim et al. They studied the pathogenic-induced changes in the lipoprotein metabolism 
in which P.gingivalis was found to induce the oxidation of high density lipoproteins, 
affecting the protective function of HDL and stimulating a proinflammatory response by 
monocytes.(24) 
Recent literature reports a link between maternal periodontal disease and adverse 
pregnancy outcomes including low birth weight, preterm labor and miscarriage. Low birth 
weight was associated with high levels of serum IgG against P.gingivalis (25). A study by 
Offenbache et al, found that 18.2% of all Preterm low birth weight cases were attributable 
to periodontal disease (26). Porphyromonas gingivalis, Actinobacillus 
actinomycetemcomitans and Treponema denticola have been detected at a significantly 
higher levels in mothers of PLBW infants (27).  
Similar to atherosclerosis, two possible biological mechanisms can mediate the 
association between periodontitis and adverse pregnancy outcomes. Dissemination of oral 
microorganisms through the bloodstream or the urinogenital tract can reach the 
fetoplacental unit. Another indirect pathway is through the circulating inflammatory 
mediators produced locally by a periodontal infection.(28)  
There is a well-established bidirectional relationship between periodontitis and Diabetes 
millets, since the severity of the periodontal disease can adversely impact the glycemic 
control(29). Various studies have reported that the prevalence and severity of non-oral 
diabetes-related complications, including retinopathy, diabetic neuropathy, proteinuria and 
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cardiovascular complications, are correlated with the severity of periodontitis.(30)(31) 
Several epidemiologic and animal studies indicated that periodontists is also associated 
with rheumatoid arthritis and respiratory diseases such as aspiration pneumonia and 
chronic obstructive pulmonary disease(23).  
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A chronic oral infection such as periodontitis is a constant potential source of 
infection and has been considered as a separate risk factor for cardiovascular diseases, 
respiratory diseases, low birth weight, increased morbidity and mortality for diabetes, 
insulin resistance, rheumatoid arthritis, obesity, osteoporosis, and complications of 
pregnancy. The possible mechanism or pathway linking oral infections to secondary 
systemic effect is: metastatic spread of infection from the oral cavity as a result of transient 
bacteremia and metastatic injury from the effects of circulating oral microbial toxins.(32) 
 
 
 
 
Figure 4. The Plausible biologic mechanism linking periodontitis to systemic 
inflammation. Hajishengallis G 2016(23) 
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TNF-a is an important factor in Periodontal inflammatory disease.  
 
 Tumor necrosis factors are a group of cytokines primarily secreted by immune cells. 
The family of tumor necrosis factor consists of two ligands; tumor necrosis factor alpha 
(TNF-a) mainly produced by phagocytes, and tumor necrosis factor beta (TNF-b), which 
is a product of cytotoxic T cells (33). 
Tumor necrosis alpha is identified as an active multifunctional molecule, linked to 
a variety of a biological processes such as cell proliferation, differentiation, apoptosis, lipid 
metabolism, and coagulation. It is a key regulating factor of inflammatory response 
produced predominantly by activated macrophages in response to trauma, infection or 
bacterial lipopolysaccharides (34) (35). It is considered the master regulator of the pro-
inflammatory cytokine cascade.  
TNF-a is believed to be involved in a wide range of pathological conditions such 
as Alzheimer's disease and osteosarcoma. In fact, it plays a critical role in the development 
of many chronic inflammatory diseases including Rheumatoid Arthritis, renal diseases and 
periodontal inflammation.(36) (37).  
There are two surface receptors for TNF, TNFAR1 and TNFAR2, which are able 
to activate different signaling pathways because of different cytoplasmic domains. Several 
cells contribute to the production of TNF in periodontal tissues, including 
monocytes/macrophages, PMN lymphocytes, endothelial cells, epithelial cells, fibroblasts 
and osteoclasts.  
TNF along with IL-1 are involved in a group of events essential for the initiation 
and propagation of inflammatory response leading to tissue destruction. They stimulate 
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adhesion molecules on leukocytes, expression of chemokines, and the production of 
inflammatory mediators such as prostaglandins to sustain the inflammatory response. 
Furthermore, they induce matrix metalloproteinases production for connective tissue 
breakdown, and stimulate osteoclast formation and activity.(38) 
Graves et al found that inhibiting IL-1/TNF reduces both inflammatory cell 
recruitment and bone loss. In a study model utilizing fourteen animals (Macaca 
fascicularis), experimental periodontitis was conducted in addition to local injection of 
function blocking receptors to IL-1 and TNF, which significantly inhibited the recruitment 
of inflammatory cells by 80%. Osteoclast formation was reduced by 67% and bone loss 
was reduced by 60% compared to the control sites, suggesting that IL-1/TNF are two 
important factors in the pathologic process of periodontitis.(39) 
TNF-α is involved at an early stage in the inflammatory cascade, as it is released 
from mast cells in response to bacterial challenge. Clinically, TNFα and IL-1β 
concentrations have been increased in gingival crevicular fluid and gingival tissue of 
periodontitis sites(40)(41), and their levels have been reported to decrease after treatment 
of periodontal disease(42)(43). 
The crucial role of these cytokines in periodontitis is further supported by reports 
explaining that attachment loss was reduced in patients with chronic periodontitis who 
received anti-TNF as a treatment for Rheumatoid arthritis. Studies also found that the 
administration of recombinant TNF-α or IL-1 to the gingiva exacerbates experimental 
periodontitis in rats (44)(45)(46). 
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Figure 5. Inflammatory mediators in Periodontal disease. Yucel-Lindberg 2013(47) 
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Interleukin (IL)-1 and tumor necrosis factor (TNF) represent proinflammatory 
cytokines that stimulate a number of events which occur during periodontal disease. These 
include the induction of adhesion molecules and other mediators that facilitate and amplify 
the inflammatory response, the stimulation of matrix metalloproteinase, and bone 
resorption. The activity of these cytokines coincides with the critical events that occur 
during periodontal disease, namely, loss of attachment and bone resorption. (48) 
 
 
 
Figure 6. The involvement of TNF-a in periodontal tissue destruction. Graves et al. 
2003.(38) 
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TNF-a mediated signaling pathway via some important factors such as TNFAIP1. 
 TNF-a production is stimulated via several signaling pathways. LPS is taken in by 
CD14 and Toll-like receptors, activating a complex of interacting pathways. MyD88 serves 
as an adaptor protein downstream of TLRs. TLRs recruits MyD88 and subsequently 
IRAKs. Then, the activated IRAK1 is released from receptor complex and forms a complex 
with TRAF6, which mediates activation of MAPK and NFkB forming the following 
signaling pathway, MyD88-IRAK- TRAF6-NIK-IBk, NFkB as well as 
MAPK(49)(50)(51).  
Another pathway involves MEK1/2, MAPK, and activator protein 1 (AP-1). The 
NFκB activation pathway is also stimulated by the regulation of IKKs activity. The 
resulting AP-1 and NFkB leads to increased transcription of TNF-α mRNA. The PI3K–
AKT pathway is initiated via phosphorylation of PI3K, which then activates AKT. The 
activation of the above-mentioned signaling pathways by LPS results in enhanced TNF-α 
synthesis.(52) 
Studies have shown that TNF-a production is responsible for the activation of many 
different gene expressions, including TNFAIP1, or tumor necrosis factor induced protein1 
(TNFAIP1)(53) (54). This protein plays a role in DNA synthesis, cell apoptosis and some 
inflammatory diseases. The TNFAIP1 gene can be induced by the exposure to TNF-a and 
IL-6 in endothelial tissues (36).  
It is also found that TNFAIP1 is highly expressed in normal cell lines but less so in 
cancer cell lines(54). TNFAIP1 shares high similarity to PDIP1 and KCTD10 in amino 
acid sequence. All of the three proteins contain a conserved BTB/POZ domain at the N-
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terminus and a PCNA binding motif (QTKV-EFP) at the C-terminus. LikePDIP1 and 
KCTD10, rat TNFAIP1 can interact with PCNA and small subunit of polymerase d (p50) 
and stimulate polymerase d activity in the presence of PCNA. These findings suggest that 
TNFAIP1 may play roles in the TNF- a signal pathway and DNA synthesis. In addition, 
TNFAIP1 may involve in the process of developing AD, innate immunity against HBV, 
and apoptosis of the HeLa cell. Recently, there was reported that Sp1 is implicated in the 
control of basal TNFAIP1 gene expression.(55) These studies indicate that TNFAIP1 may 
play critical roles in developmental and disease processes. The exact physiological function 
and the acting mechanism of TNFAIP1 have not been reported. It is clear that the 
interaction of proteins is a major mechanism in the regulation of various fundamental 
cellular processes. RhoB, a tumor suppressor, has emerged as an interesting cancer target, 
and extensive studies aimed at understanding its role in apoptosis have been performed. 
The interaction between RhoB and TNFAIP1 was demonstrated in vivo through co-
immunoprecipitation studies and in vitro binding assays. The partial colocalization of 
RhoB and TNFAIP1 in endosomes suggests that RhoB-TNFAIP1 interactions may have a 
functional role in apoptosis. TNFAIP1 elicited proapoptotic activity, while simultaneous 
expression of RhoB and TNFAIP1 resulted in a dramatic increase in apoptosis in HeLa 
cells. Moreover, it was shown that RhoB interacts with TNFAIP1 to regulate apoptosis via 
a SAPK/JNK-mediated signal transduction mechanism.(56)  
Given all these information about the functional activity of TNFAIP1, more 
information is still needed to comprehend the process of gene activation, signaling 
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pathways and interactions. The regulatory mechanisms that control TNFAIP1 expression 
is still not clearly identified.(55) 
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The biological functions of TNFAIP1 examined with my novel method 
Several methods and techniques have been used to determine the activity of a 
certain gene or their protein products, such as western blot analysis, polymerase chain 
reaction (PCR) and DNA transfection in cells. Transfection is a powerful analytical tool 
enabling study of the functions of gene and regulation of their protein functions.  
Transfection is the introduction of foreign nucleic acids into cells to produce 
genetically modified cells. The introduced genetic materials (DNAs and RNAs) exist in 
cells either stably or transiently depending on the nature of the genetic material. For stable 
transfection, introduced genetic materials are integrated into the host genome and sustain 
transgene expression even after host cells replicate. In contrast, transiently transfected 
genes are only expressed for a limited period of time and are not integrated into the 
genome.(figure 7) (57)(58)(59) 
There is a wide variation with respect to transfection efficiency, cell toxicity, the 
level of gene expression (60). DNA transfection provides a high efficiency (≥60%) in some 
selective adherent cells such as U2OS (human bone Osteosarcoma Epithelial cells, 
ATCC® HTB-96TM (61) or mouse RAW 264.7 cells (ATCC® TIB-71TM (62). DNA 
transfection is rarely used in THP-1 cells (human monocyte- like cells, ATCC® TIB-
202TM (63), since this proposed protocol cannot generate a high transfection efficiency in 
THP-1 (≤5%) even though these suspension cells are pre-matured by PMA (phorbol 12-
myristate 13-acetate, Sigma) treatment and become adherent cells prior to DNA 
transfection (64)(65).  
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The difference between stable and transient DNA transfection: in transient 
transfection, the transfected material enters the cell but does not get integrated into the 
cellular genome. In stable transfection, the plasmid DNA successfully integrates into the 
cellular genome and will be passed on to future generations of the cell.  
 
 
Figure 7. Schematic diagrams of two different transfections. (a) Stable transfection. 
Foreign DNA (red wave) is delivered to nucleus by passage through the cell and nuclear 
membranes. Foreign DNA is integrated into the host genome (black wave) and expressed 
sustainably. (b). Transient transfection. Foreign DNA is delivered into the nucleus but is 
not integrated into the genome. Kim and Eberwine 2010 (59) 
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Since THP-1 cells are an important type of human monocyte-like cell and widely 
used for research in the area of human pathology and immunology, we were interested in 
finding a better method to increase DNA transfection efficiency in these cells. We have 
recently discovered that THP-1 and Myeloma (human cells, ATCC® TIB-196TM) 
suspension cells undergo multilayer aggregation and accumulate to the bottom of a 1.5 ml 
Eppendorf tube after static culture for two or more hours as shown in Figure 8. This 
important feature provided us with the ability to increase transfection efficiency in 
suspension cells. In this paper, we describe transfection of our recombinant plasmid DNA 
with a full length of GFP gene in THP-1 cells with ∼13.5% transfection efficiency. The 
usage of other DNA such as human TNFAIP1(65) or human CXCL1 (65) for DNA 
transfection in THP-1 or Myeloma suspension cells also confirmed this point.  
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The suspension THP-1 cells start to accumulate at the bottom of the Eppendorf tube 
after static culture, providing a better condition for a direct transfection and eliminating the 
need for pre-maturation using PMA.  
 
 
 
 
 
 
 
Figure 8. Diagram of cell aggregation. THP-1 suspension cells were multilayer 
aggregated in a 1.5 ml Eppendorf tube for 3 h of the static culture.(66) 
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Does TNFAIP1 function as an activator or suppressor to TNF-a ? 
Recently, we have been able to identify a unique and strong association between 
TNFAIP1 and TNF-a production. TNFAIP1 is activated in response to TNF-a gene 
expression, and surprisingly, we found that the overexpression of TNFAIP1 also exerts a 
reverse stimulatory effect, activating the synthesis of TNF-a. Another imperative finding 
is that this Tow-sided pathway is mediated via the activation of PI3kinase and the AP-1 
transcriptional factor will translocate to the nucleus and bind to the promoter region of the 
TNF-a gene to activate its gene expression and ultimately TNF-a secretion. We also found 
that TNFAIP1 functions as an activator for TNF-a gene expression in early stages and 
suppresses TNF-a in late stages by binding to the Caspase 1 apoptotic gene promoter 
region.  
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Aims 
1- To investigate the factors involved in the TNFAIP1 mediated signaling pathway in 
response to LPS in mouse macrophage, to discuss the underlying mechanism that 
regulates the TNFAIP1, and to identify the downstream pathway for this gene.  
2- To establish a new efficient technique for DNA transfection in suspension cells, 
which was used to study the biological functions of TNFAIP1 in human THP-1 
cells (human macrophages like cells).  
3- To provide a conclusive understanding for the double-sided signaling pathway 
between the TNFAIP1 and TNF-a gene expression, by analyzing their activation 
for certain apoptotic gene expressions.  
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MATERIALS AND METHODS 
Cells and culture 
- RAW cells, THP-1 cells or Myeloma cells were cultured in RPMI-1640 media 
(Cat#: 11875–093, Life Technologies, NY) and supplemented with 10% FBS at 
37°C in a 5% CO2 atmosphere. Cell splitting and media changing were done 
frequently to ensure cell viability and to provide a larger storage for future 
experiments. Trypsin-EDTA (0.25%) was used prior to split mouse RAW cell 
macrophages. (Figure 9) 
- Top 10 cells (Invitrogen) were used for the DNA construction following the 
manufacturer’s instructions: 
Cells were thawed on ice. Then, 1–5 µL of the desired DNA was pipetted directly 
into the vial of competent cells and mixed by tapping gently. The mixture was then 
incubated on ice for 30 minutes. After, the mixture is incubated for 30 seconds in 
the 42°C water bath, removed from the 42°C bath then placed on ice for 5 minutes. 
20–200 µL from the transformation vial were spread on a labeled LB agar plates 
and incubated at 37°C overnight. Colonies were picked up for culture and DNA 
preparation. 	  
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Figure 9. The RPMI medium used for the cell culture of mouse RAW cells and human 
THP_1 cells. 
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Figure 10. Samples of Human THP_1 cells and Mouse RAW cells observed under light 
microscopy. 
 
 
 
 
RAW	cells THP-1	cells 
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Plasmid construction 
(I) GFP (contained in pLenti7.3/V5, Thermo Fisher Scientific) was cloned with 
a CCL2 promoter as a recombinant plasmid DNA.  
(II) TNFAIP1 (a full-length of human TNFAIP1 gene) was kindly provided by 
Harvard University (Clone ID: HsCD00000573) and used as template DNA 
for Polymerase chain reaction (PCR). TNFAIP1 full length cDNA was 
generated by PCR with the primer pair 5′-
ATGTCGGGGGACACCTGCCTG - 3′ & 5′-
CTAGTCGCGATGGGTAGACTG -3′. The PCR-amplified DNA 
fragment was inserted into pcDNA3 as a recombinant plasmid DNA.  
(III) CXCL1 (a full-length of human CXCL1 gene) was kindly provided by 
Harvard University (Clone ID: HsCD00326770) and used as template DNA 
for PCR. CXCL1 full length cDNA was generated by PCR with the primer 
pair 5′-ATGGCCCGCGCTGCTCTCTCC-3′ and 5′ 
TCAGTTGGATTTGTCACTGTT-3′. The PCR-amplified DNA fragment 
was inserted into pcDNA3 as a recombinant plasmid DNA.  
(IV) TNFAIP1 promoter (a full-length of human TNFAIP1 promoter gene) was 
generated by PCR with the primer pair. The PCR-amplified DNA fragment 
was inserted into pGL3-basic as a recombinant plasmid DNA. Three cloned 
DNAs above were confirmed by DNA sequencing. 
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Figure 11. Thermal cycler. This machine was used to amplify DNA via PCR. 
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Figure 12. Appearance of plasmid-containing bacterial colonies on an antibiotic-
containing agar nutrient plate. 
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Figure 13. Shaking Incubator was used to incubate the Plasmid-containing bacterial cells 
to be used for DNA-preparation and purification. 
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Figure 14. The pcDNA3 kit was used to insert the TNFAIP1 DNA fragment into 
recombinant plasmid DNA. 
 
 
 
	 33 
DNA transfection  
DNA transfection in cells was performed with a kit (Lipofectamine® 2000, Thermo 
Fisher Scientific) according to the manufacturer's instructions.  
For mouse RAW cells: Cells were cultured for 70-90% confluency at the time of 
transfection. Lipofectamine reagent and DNA were both diluted in Opti-MEM medium and 
incubated for 20 minutes. Diluted DNA was then added on the diluted Lipofectamine 
reagent and incubated for 20 minutes at room temperature. The mixture is then added to 
the cells and incubated at 37°C for 48 hours.  
For THP-1 and Human Myeloma cells: DNA transfection in suspension cells using the 
above-mentioned method provides less than 5% transfection efficiency. The same 
technique is followed except simple changes comprises the collection of the cultured cells 
into a 1.5 ml Eppendorf tube before the application of the DNA-Lipofectamine mixture.  
Inhibitors 
Celastrol ( inhibitor of NFkB Cat code: ant-cls, Invivogen), SB202190 ( MAP 
kinase inhibitor, Cat. Code: tlrl-sb90, Invivogen), Ruxolitinib ( JAK inhibitor,Cat. Code: 
tlrl-rux, Invivogen), or Buparlisib ( PI3K inhibitor Cat # S2247, Sellekchem) was dissolved 
in 1% DMSO just before use. 
 
 
 
	 34 
 
 
 
 
Figure 15. Lipofectamine reagent kit that was used to perform DNA transfection into 
macrophages. 
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ELISA  
The treated media from Mouse RAW cells, THP-1 cells or Myeloma cells were 
subjected to ELISA for TNF-α detection with a kit (Cat#:KHC3011, Invitrogen) according 
to the manufacturer’s instructions: 
The provided micro well strips were washed twice with approximately 400 µL wash buffer 
per well with thorough aspiration of micro well contents between washes. After the last 
wash step, wells were emptied by tapping the micro well strips on absorbent pad or paper 
towel to remove excess wash buffer. Then, 50 µL of the sample was added to the wells, 
plus 50 µL of Biotin-Conjugate to all wells. Wells were covered with an adhesive film and 
incubated at room temperature for 2 hours, on a microplate shaker. Then, wells were 
washed 6 times. 100 µL of diluted Streptavidin-HRP was added to all wells, including 
blanks. Wells were covered with an adhesive film and incubated at room temperature for 
1 hour on a microplate shaker. Micro well strips were washed 6 times. 100 µL of TMB 
Substrate Solution was added to all wells and incubated at room temperature for about 30 
min avoiding direct exposure to intense light. The color development on the plate was 
monitored and the substrate reaction stopped by quickly pipetting of 100 µL of stop 
solution into each well. The absorbance of each micro well was read on a 
spectrophotometer using 450 nm as the primary wave length.  
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Figure 16. TNF-a ELISA kit. 
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ELISA for Caspase 1 was done according to the following protocol:  
Samples are added to corresponding wells (100µl for each well). Wells are sealed 
with adhesive tapes, and incubated at 37℃ for 90 min. ELISA plates are washed 2 times. 
The biotinylated Mouse Caspase-1 antibody liquid which was prepared 30min in advance 
are added to each well (100µl for each). Wells are sealed with adhesive tapes and incubated 
at 37℃ for 60 min. ELISA plates are washed 3 times 9. The enzyme-conjugate liquid is 
prepared 30 min in advance and added to each well except blank wells (100µl for each). 
The reaction wells are then sealed with adhesive tapes and incubated at 37℃ for 30 min.  
Wells are washed 5 times. 100µl of the color reagent liquid was added to each individual 
well (also into blank well), and incubated in a dark incubator at 37℃. When the color for 
high concentrations of the standard curve became darker and a color gradient appears, the 
hatching was stopped by adding 100µl Color Reagent C to the individual wells (also into 
blank well) and mixed well.  
ELISA immunoreactivity was quantified using a microplate reader (Model 680, 
Bio-Rad). The data were analyzed and then graphed.  
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Figure 17. Caspase 1 ELISA kit. 
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Figure 18. Color development of samples on the micro well strip. Reaction is ready to be 
stopped and read using a microplate reader. 
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Figure 19. Microplate reader, used to measure the ELISA immunoreactivity. 
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Western blot analysis 
RAW cells, THP-1 cells or human myeloma cells were treated and cultured 
overnight. Whole-cell protein or nucleus protein from these pre-treated cells were purified 
according to the following protocol: 
Cell culture dish is placed on ice and washed the with ice-cold PBS. After aspirating 
the PBS, then, ice-cold lysis buffer is added (1 mL per 107 cells/100 mm dish/150 cm2 
flask). Cells are scraped off the dish using a cold plastic cell scraper, then, the cell 
suspension is gently transferred into a pre-cooled microcentrifuge tube. Centrifuged in a 
microcentrifuge at 4°C. Tubes are then gently removed from the centrifuge and placed on 
ice. The supernatant is aspirated and placed in a fresh tube kept on ice, the pellet is 
discarded. 
Proteins were equally loaded according to protein concentration and run in an SDS-
PAGE gel along with molecular weight marker for 1–2 h at 100 V. Protein bands were 
transferred to a membrane, which is then activated with methanol for 1 min and rinsed with 
transfer buffer before preparing the stack. Membrane Block was done using blocking buffer 
for 1 h at room temperature or overnight at 4°C 2. Samples were then blotted with 
antibodies against MAPK, PI3K, NFkB (p65), JAK, TNFAIP1, Ap-1, or actin as a control. 
Membrane is washed in three washes of TBST, 5 min each, then incubated with the 
recommended dilution of conjugated secondary antibody in blocking buffer at room 
temperature for 1 hour. Once again, membrane is washed in three washes of TBST, 5 min 
each. For signal development, the excess reagent is removed and the membrane is covered 
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in transparent plastic wrap. To acquire an image, darkroom development techniques was 
used for chemiluminescence. 
Statistical analysis  
All experiments were performed in triplicate and statistical analyses were 
conducted with the SAS software package. All data were normally distributed. For multiple 
mean comparisons, we conducted analysis of variance (ANOVA), while we used the 
Student's t-test for single mean comparison. For time-course study, we used a two-way 
repeated measure ANOVA. P values less than 0.05 were considered significant.  
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RESULTS 
1. The interacting proteins in the LPS induced TNF-α production. 
TNF-a signal transduction pathways are complex and determined by many interacting 
signaling networks which is not yet fully understood except for transcription factor NFkB, 
a key component known for TNF-a signal transduction (34). In order to identify the factors 
involved in the TNF-α signaling pathway, Western blot analysis was done using antibodies 
against MAP kinase, PI3K, NFkB, JAK, and TNFAIP1, and actin was used as a control. 
Macrophages were treated with E. coli, P. gingivalis and LPS. We found that p-MAPK, p-
PI3K, NFkB, p-JAK and TNFAIP1 were activated after treatment of macrophages with P. 
gingivalis or LPS. (As shown in Figure 20) 
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Figure 20. The cells were untreated as control or treated with E. coli (1x108/ml), P.g 
(1x108/ml), or LPS (0.1µg/ml). Proteins from each test cell were purified and detected 
with antibodies against to MAPK, PI3K, NFkB (p65), JAK, TNFAIP1 or Actin as 
control. Intensity of protein level from untreated cells was assigned to a base value 
(100%). Intensity of protein level from other treatments was calculated relative to this 
base value. Triplicate assays were conducted. 
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2.  Cloning of TNFAIP1. 
In order to study the biological functions of the TNFAIP1 gene. Full length TNFAIP1 
cDNA was generated by PCR with the primer pair 5′-ATGTCGGGGGACACCTGCCTG 
-3′ &  5′-CTAGTCGCGATGGGTAGACTG -3′. The PCR-amplified DNA fragment was 
inserted into pcDNA3 as a recombinant plasmid DNA. (Figure 21, 22). 
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Figure 21. DNA running of PCR products of pcTNFA1-4. 
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      Figure 22.  The physical map of pcTNFA1-4 cDNA construction. 
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3.  TNFAIP1 overexpression induces TNF-a production. 
It is known that TNF-α production is induced by overexpression of TNFAIP1 in cells 
(55). Figure 23 shows the effect of different DNA concentrations of TNFAIP1 in 
macrophages on TNF-α induction. ELISA analysis revealed a positive association between 
TNFAIP1 and TNF-α, as the production of TNF-α was significantly higher in the test 
groups compared to the untreated control group, which was furtherly increased up to four 
folds upon increasing the concentration of TNFAIP1 from 0.1 µg to 1 µg. This result 
suggests that TNF-α production is induced by TNFAIP1. 
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The TNF-a production induced by overexpression of TNFAIP1 was confirmed by ELISA 
analysis of dose course.  
 
 
 
 
 
 
 
 
 
 
 
Figure 23. Dose course of TNFAIP1. Macrophages were untreated as a control or 
transfected with 0.1µg or 1µg pcTNFA1-4 for 40 hours. Cells were washed with PBS and 
cultured for 2 more hours (No.4 &5). The treated medium from each group was collected 
and used to measure their TNF-α production by ELISA. 
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4.  Blocking MAPK, PI3K and JAK downregulates the TNF-a production. 
The role of MAPK, PI3K, JAK, and NFkB in the TNF-a production pathway has been 
studied by using their specific inhibitors. Figure 24 shows that inhibition of (MAPK, JAK, 
PI3K) significantly reduced TNFAIP1-induced TNF-a secretion. However, this was not 
the case with NFkB inhibitor, which in contrast, induced TNF-a production. This result 
indicates that TNFAIP1-induced TNF-a production is independent of the NFkB pathway. 
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Inhibition of certain transcriptional factors involved in the pathway of TNF-a production 
exhibits different effects on the activation of TNF-a gene expression.  
 
 
 
 
Figure 24. The effect of different inhibitors on DNA overexpression-mediated TNF-α 
expression. Macrophages were untreated as a control or transfected with 1µg pcTNFA1-4 
for 40 hours, and cells were washed with PBS. Cells were individually treated with 
inhibitor of NFkB (10uM), MAPK (10uM), JAK (10uM), or PI3K (10uM) for 2 hours. 
The treated medium from each test group was collected and used for measurement of 
TNF-α production by ELISA. 
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5. Improved DNA transfection efficiency without PMA in THP-1 cells  
Confirmation of the previous results on a human model requires the utilization of 
human macrophages. However, DNA transfection is rarely used in THP-1 cells (human 
monocyte-like cells) since this proposed protocol cannot generate a high transfection 
efficiency in THP-1 cells (≤ 5%), even though these suspension cells are pre-matured by 
PMA (phorbol 12-myristate 13-acetate, Sigma) treatment and become adherent cells prior 
to DNA transfection. 
In order to prove this, DNA transfection was performed. As shown in Figure 25, 
PMA treatment of cells before (panel B) or after DNA transfection (panel C) did not affect 
cell maturation (186 cells adhered on the plate in panel B, 192 cells were adhered on the 
plate in panel C). However, DNA transfection before and after PMA treatment showed a 
large difference in efficiency (13.5% induced by DNA transfection before PMA treatment 
in panel F or only 1.6% induced by DNA transfection after PMA treatment in panel E). 
This suggests that PMA treatment does not help DNA transfection, and THP-1 cells in the 
1.5 ml Eppendorf tube without PMA treatment may induce higher transfection efficiency.  
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Figure 25. Image of GFP in the treated THP-1 cells. 1 × 105 THP-1 cells (panels A, B, D 
or E) pre-cultured in one well of 24 well/plate were treated with PMA overnight, and 
washed with PBS. Continuously, cells were mock-transfected as the negative control 
(panels A & D) or transfected with 1 µg GFP recombinant plasmid DNA (Tang and Amar 
2015) as the positive control (panels B & E) for 16 h. Meanwhile, 1 × 105 THP-1 cells 
(panels C & F) as the test group were collected and added into a 1.5 ml Eppendorf tube 
and then transfected with 1 µg GFP recombinant plasmid DNA for 16 h. Cells were 
transferred into one well of 24 well/plate and then treated with PMA overnight. All cells 
(panels A–F) were washed with PBS, observed and photographed in visible light to 
calculate the number of cells (204 cells as total in panel A, 186 cells in panel B, and 192 
cells in panel C). Then, fluorescent light of the cells was observed in signal location of 
panels D (none), E (3 signals), or F (26 signals) using an Olympus BX40 microscope at 
×200 magnification. Image analysis was performed with Image-Pro plus 5.0. The 
estimated transfection efficiency is 1% for the positive control (3/186 = 1.6%, panel 
E&B) and 13.5% for the test group (26/192 = 13.5%, panel F&C) compared to the 
negative control (Panels D & A). (66) 
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6. Induction of TNF-α production by TNFAIP1 DNA transfection in THP-1 cells 
Since it is known that the overexpression of TNFAIP1 in cells induces TNF-α 
production, DNA transfection of TNFAIP1 recombinant plasmid in THP-1 suspension 
cells without PMA treatment was used to further confirm this finding above. As shown in 
Figure 26, the time course of TNFAIP1 showed that the transient transfection of increasing 
concentrations of TNFAIP1 from 0.5 to 2 µg caused a concomitant increase in TNF-α 
production compared to the control.  
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Figure 26. Dose course assay. 1 × 105 THP-1 cells were collected and added into each 
1.5ml Eppendorf tube and then respectively transfected with 0.5µg, 1µg, or 2µg of 
TNFAIP1 recombinant plasmid DNA for 16 h. The supernatant from each group was 
used to measure TNF-α concentration by ELISA. Data were analyzed and then graphed. 
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7. Increase of DNA transfection efficiency by aggregated multilayer cells 
To confirm whether the aggregated multilayer cells help to increase transfection 
efficiency, DNA transfection of THP-1 suspension cells in different containers was tested. 
As shown in Figure 27, without PMA treatment, DNA transfection of cells in one well of 
24 well/plate (No.2) did not show a significant change of DNA transfection efficiency 
compared to the untreated control (No.1). However, DNA transfection of cells in a 1.5 
Eppendorf tube (No.3) showed a significant efficiency, about three times more than the 
treatment of cells in the 24 well/plate.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 57 
 
 
 
Figure 27. ELISA Analysis of DNA transfection in a different container. 1 × 105/0.5 ml 
THP- 1 cells in each well of 24 well/plate were untreated as a control (group 1) or 
transfected with 1 µg TNFAIP1 recombinant plasmid DNA as the positive control (group 
2) for 16 h. Meanwhile, 1 × 105 THP-1 cells/0.5 ml was added into a 1.5 ml Eppendorf 
tube and transfected with 1 µg TNFAIP1 DNA as the test (group 3) for 16 h. The medium 
from each group were collected and was analyzed by ELISA to detect their TNF-α 
concentration. The TNF-α concentration of each group was compared to the effect of the 
negative control group (untreated) as the 100% baseline and their compared ratio (%) is 
indicated. Data were analyzed and then graphed. 
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8. Time course assay 
In order to examine the effect of transfection time on efficiency with this new method, 
an equal amount of THP-1 suspension cells (1 × 105 cells in one well of 24 well/plate or a 
1.5 ml Eppendorf) was respectively transfected with the TNFAIP1 recombinant plasmid 
DNA or untreated as a control for 16, 24, 36, or 48 hrs. Figure 28 shows that the DNA 
transfection of cells for 36 h in the 1.5 ml Eppendorf had the best transfection efficiency, 
with a 2.44-fold increase in TNF-α production compared to the treatment of cells in the 24 
well/plate.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 59 
 
 
 
 
 
 
Figure 28. ELISA. The pre-cultured 1 × 105 THP-1 cells with 0.5 ml media were added 
into a well of the 24 well/plate or Eppendorf tubes. Then, cells were transfected with 1 µg 
TNFAIP1 recombinant plasmid DNA or untreated as a control for 16, 24, 36, or 48 hours. 
The supernatant from each group was collected and were analyzed by ELISA to detect 
their TNF-α concentration. The TNF-α concentration of each group was compared to the 
effect of the negative control group (untreated) as the 100% baseline and their compared 
ratio (%) is indicated. Data were analyzed and then graphed. 
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9. Independence of DNA transfection from media volume 
To identify the effect of media volume in a 1.5 ml Eppendorf on DNA transfection 
efficiency, equal amounts of THP-1 cells were added into 1.5ml Eppendorf tubes, 
respectively, with different volumes (100 µl, 300 µl, or 500 µl) of culture media, and then 
transfected with the same amount (1µg) of TNFAIP1 recombinant plasmid DNA. 
Surprisingly, treatment with different volumes of media showed similar TNF-α production 
in response to DNA transfection (Figure 29). It suggests that cell multilayer aggregation, 
regardless of media volume, is a necessary condition for DNA transfection. Essentially, 
higher transfection efficiency depends on either more DNA or more cells.  
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Figure 29. ELISA. An equal number of cells (1 × 105 THP-1) were respectively loaded 
into 1.5ml Eppendorf tubes, with the untreated tube as the control and the transfected 
tube with 1 µg TNFAIP1 recombinant plasmid DNA as the test group. 0.1 ml, 0.3 ml, or 
0.5 ml media was added to the cells in test groups and 0.5 ml media for the control group. 
Cells were continuously cultured at 5% CO2, 37 °C for 36 hours. The supernatant from 
each group was collected and analyzed by ELISA to detect TNF-α con- centration. TNF-
α concentration of each group was compared to the negative control (untreated) as the 
100% baseline and their compared ratio (%) is indicated. Data were analyzed and then 
graphed. 
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10. The capability of our new method  
Besides TNFAIP1 recombinant plasmid DNA, we also tested another DNA 
(CXCL1) for transfection in THP-1 suspension cells by our new method. As shown in 
Figure 30, the transfection of CXCL1 recombinant plasmid DNA induced TNF-α 
production four folds higher than the untreated control. Furthermore, this new DNA 
transfection method was positively confirmed by using human Myeloma suspension cells 
as shown in Figure 31.  
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Figure 30. ELISA. An equal number of THP-1 cells in each 1.5 ml Eppendorf tube was 
transfected with 1µg TNFAIP1 recombinant DNA or 1µg CXCL1 recombinant plasmid 
DNA or untreated as a control. Tubes were then incubated at 5% CO2, 37 °C for 36 h. 
The supernatant from each group was collected and analyzed by ELISA to detect its 
TNF-α concentration. The TNF-α concentration of each group was compared to the 
negative control (untreated) as the 100% baseline and their compared ratio (%) was 
indicated. Data were analyzed and then graphed. 
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Figure 31. ELISA analysis 4. Human THP-1 or Myeloma suspension cells in each 1.5 ml 
Eppendorf tube was either untreated as the negative control or transfected with 1 µg 
TNFAIP1 recombinant plasmid DNA as a test group for 36 hours. The supernatant from 
each group was collected and analyzed by ELISA to detect its TNF-α concentration. Data 
were analyzed and then graphed. 
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11. TNFAIP1 induces Caspase 1 gene expression. 
Previous reports showed that Caspase 1 gene is induced by TNF-α via activation of 
p-73 (67). To test the effect of TNFAIP1 on Caspase 1 gene and protein expression, 
TNFAIP1 cDNA was transfected into mouse macrophages, and the levels of active Caspase 
1 gene was measured using ELISA. As shown in figure 32, treatment of TNFAIP1 resulted 
in an increase in Caspase 1 expression. This result suggests that TNFAIP1 overexpression 
functions upstream of the Caspase 1 gene. 
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Figure 32. ELISA Analysis. Macrophages were untreated as control (No.1), transfected 
with 1 µg of pcDNA3 as a positive control (No.2), or transfected with 1 µg TNFAIP1 
(No.3). The treated medium from each test group was collected and used for 
measurement of Caspase 1 production by ELISA. 
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12. TNFAIP1-induced Caspase 1 downregulates the production of TNF-a. 
The previous results showed that Caspase 1 is increased in response to TNFAIP1,  
a potential controlling factor for TNF-a. In order to measure the levels of TNF-a and 
Caspase-1 simultaneously, we performed a time course assay for TNF-a and Caspase 1 
expression in mouse RAW cells after treatment with TNFAIP1 as shown in figure 33. We 
found that the Caspase 1 gene expression steadily rises overtime, while TNF-a starts to 
decrease after reaching its maximum levels at the 10-hour time point. This result implies a 
two-sided association between TNFAIP1 and TNF-a, as TNFAIP1 functions upstream and 
downstream for TNF-a gene expression in a time sensitive fashion. It activates TNF-a 
gene expression in early stages, and suppresses its production in later stages.  
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Figure 33. Time course assay. The treated medium from TNFAIP1-treated macrophages 
was collected at different time points (0-20 hrs), and the concentration of TNF-a or 
Caspase-1 were respectively measured by ELISA. 
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DISCUSSION 
 
Tumor Necrosis Factor is an important cytokine that mediates many inflammatory 
processes, and the regulating mechanism for TNF-a has been extensively studied(68). 
TNFAIP1 gene is activated as an immediate response to TNF-a production. Previous 
reports proposed a critical role for TNFAIP1 and related proteins in different disease 
processes (69)(70). Nevertheless, the molecular mechanism regulating TNFAIP1 in 
relation to TNF-a is not completely understood. TNF-α is present in the microenvironment 
of many types of tumors, and is known to promote tumor progression. Overexpression of 
TNFAIP1 or TNFAIP2 correlates with tumor invasion and metastasis, and serves as an 
independent prognostic indicator for breast cancer (71) and nasopharyngeal carcinoma 
(72). The TNFAIP2 miRNA binding site (s8126 T>C SNP) is also correlated with a 
significantly elevated risk of gastric cancer, suggesting a marker for susceptibility to gastric 
cancer (73).  
Moreover, the function of TNFAIP requires further research in cancer. First, 
TNFAIP1 confers acquired resistance to paclitaxel, while knockdown of TNFAIP1 was 
found to increase the tumor response to paclitaxel (74), suggesting that TNFAIP may 
represent a valuable therapeutic target for the treatment of cancer. Furthermore, TNFAIP1 
was found to be downregulated by miR-372/-373 and participates in cell apoptosis and 
proliferation via the NFκB pathway (75)(76).  
Few studies have shown that TNFAIP1 inhibits the transcriptional activities of 
NFkB (54). The knockdown of TNFAIP1 downregulated the expression of NFkB at the 
translational level in OS cells, suggesting that TNFAIP1 may promote the progression of 
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Osteosarcoma (OS) through activation of the NFkB pathway. The high expression of 
TNFAIP1 is associated with the distant metastasis of OS, and knockdown of TNFAIP1 
inhibits the growth and invasion, and induces apoptosis in OS cells through inhibition of 
the NFkB pathway, suggesting that TNFAIP1 may act as a potential therapeutic target for 
the treatment of cancer.(36). 
It has been previously reported that TNFAIP1 was shown to be expressed at a high 
level in normal cells and was downregulated in several cancer-derived cell lines. In tumor 
cells, TNFAIP1 can act through pleiotropic mechanisms, including stimulation of cell 
proliferation, survival, migration, and invasion (77)(70). NFkB is one of the most important 
intracellular nuclear transcription factors, and it plays a central role in the transcriptional 
regulation of many genes that are influenced by various stimuli. It has also been shown that 
NFkB activity inhibits apoptosis in cancer cells. In a previous study, we found that 
TNFAIP1 and KCTD10 suppressed the transcriptional activities of NFkB, leading to 
decreased cell survival by transactivating anti-apoptotic genes downstream of NF-κB 
(54)(78).  
Caudatin, a C-21 steroidal glycoside isolated from Chinese herbs, has a long history 
of use for the treatment of multiple diseases, including cancers, was found to have an anti-
proliferative and pro-apoptotic activities in uterine cancer cells, at least partially, via the 
caspase-dependent apoptotic pathway and the TNFAIP1/NFkB signaling pathway. Thus, 
targeting TNFAIP1 may be an effective strategy to control tissue destruction in uterine 
cancer patients.(79)  
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To help us study the nature and activity of this gene, we found a new simple and 
efficient method to perform a DNA transfection into human macrophages. DNA 
transfection is an important technology for bioengineering. However, this technique is 
often used on adherent cells rather than cells in suspension due to the low transfection 
efficiency obtained in suspension cells such as THP-1 cells (generally only ≤ 5%). The 
adherent cells such as mouse RAW cells or human cancer U2OS cells are beneficial to 
DNA transformation, sometimes with up to 20%–60% transfection efficiency. Therefore, 
we tried to improve the DNA transfection efficiency in THP-1 cells when in use. With the 
method described here, we can increase the DNA transfection efficiency in THP-1 or 
Myeloma suspension cells. Additionally, transfection of TNFAIP1 or CXCL1 recombinant 
plasmid DNA in THP-1 cells induces a high level of TNF-α protein. As TNFAIP1 and 
CXCL1 is known to be related to a number of important inflammatory diseases, this new 
method is expected to be highly conducive for the evaluation of inhibitors that suppress the 
activation of these genes and expression.  
We used 1.5 ml Eppendorf to hold cells for DNA transfection in this paper. Other 
tubes, such as 2 ml or 0.5 ml Eppendorf tube, also show the positive results for DNA 
transfection as long as the shape of these tube bottoms is the Inverted cone (data not 
shown).  
Interestingly, while the THP-1 cell aggregation at the bottom of a tube posed the 
possibility of dead cells/debris, most cells (≥95%) were confirmed to be vital as defined by 
Trypan Blue staining method. The use of Lipofectamine reagent for DNA transfection in 
THP-1 or Myeloma cells, and the use of other transfection reagents such as FuGENE®6 
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(Promega) for DNA transfection in THP-1 cells also showed similar transfection efficiency 
(data not shown).  
Overall, the new method described in this paper provides an important foundation 
for those interested in: 1) Simplifying the process of DNA transfection of cells in 
suspension, 2) Removing the necessity to mature the suspension cells with PMA, 3) 
Improving repeatability, and 4) Reducing cost value.  
The results presented here shows that TNFAIP1has a biphasic action on the TNF-
a gene expression in time dependent manner. It upregulates the TNF-a gene expression in 
the early stages, via PI3kinase and AP-1, and in the late stages, it suppresses the TNF-a 
production through activating the Caspase 1 apoptotic gene. Overexpression of Caspase 1 
gene downregulates the TNF-a gene expression by signaling apoptotic genes such as p73 
leading to cell apoptosis. 
These significant findings emphasize a possible involvement of this gene in the 
persistent rising of TNF-a levels in chronic inflammatory diseases as a result of the unique 
reversible pathway between TNFAIP1 and TNF-a.  
Given these facts, inhibition of TNFAIP1 could emerge as a therapeutic target to 
fight the progression and development of a large number of inflammatory conditions. As 
part of a future plan we have been able to identify the promotor gene for TNFAIP1, and 
future studies should focus on controlling TNFAIP1 gene expression via blocking its 
promotor gene and other important factors may be involved in this pathway including 
LITAF.  
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Conclusions 
 
1. MAP kinase, JAK, or PI3K, may be involved in TNF-α gene expression in LPS-
dependent pathway.  
2. TNFAIP1 expression can induce TNF-a production in mouse macrophages and 
vice versa. 
3. TNFAIP1 gene expression in response to LPS is independent of NFkB-mediated 
signaling pathway.  
4. The animal model has been confirmed by using both mouse macrophage-like cells 
(RAW cells) and a human macrophage-like cells (THP-1 cells). 
5. The signaling pathway for the activation of TNF-a production in early stages is: 
LPS/ TNFAIP1/ PI3Kinase/ AP-1/ TNF-a. 
6. TNFAIP1 acts as a suppressor in later stage to down-regulate TNF-α gene 
expression via the following signaling pathway: LPS/ TNF-a/ TNFAIP1/ Caspase 
1/ Apoptotic genes/ Degradation of TNF-α/ Cell apoptosis. 
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